- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Ryan Scott | Authors
Itolizumab Prompts Release of Cell-Surface CD6 in aGVHD
April 26, 2022
In the phase 1b EQUATE trial, patients with acute graft-versus-host disease had decreased levels of cell-surface CD6 when treated with itolizumab.
Updated KEYNOTE-042 Data Show Sustained Survival Benefit at 4 Years in Chinese Patients With Frontline NSCLC
April 10, 2022
Data presented from the 4-year follow-up to the phase 3 KEYNOTE-042 trial display continuous survival benefit of pembrolizumab vs chemotherapy in Chinese patients with untreated non–small cell lung cancer.
Clinical Trial for Patients With Previously Treated Recurrent or Metastatic Cervical Cancer Is Exploring Ociperlimab Plus Tislelizumab Combo
March 19, 2022
An anti-TIGIT/anti–PD-1 combination approach with ociperlimab plus tislelizumab will be examined in a phase 2 study of patients with previously treated recurrent or metastatic cervical cancer.